Le Lézard
Classified in: Health, Science and technology
Subjects: PER, PET, ANW

Sentrxtm Animal Care, Inc. Announces Formation of Their Ophthalmology Scientific and Medical Advisory Board


SALT LAKE CITY, Jan. 11, 2022 /PRNewswire/ -- Sentrx, an animal health company that transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals, today announced the formation of a US-based Ophthalmology Scientific and Medical Advisory Board (OSMAB) comprised of veterinary and scientific leaders in ophthalmology and clinical trial design. The board will be chaired by Chief Scientific Officer, Sarah Atzet, Ph.D. and will work closely with management to advance the company's clinical pipeline development in the US and the utility of its platform BioHAncetm technology, a patented molecular matrix of cross-linked hyaluronic acid (HA).

"We've assembled a board of prestigious scientific and medical thought leaders to provide Sentrx with relevant and informed counsel in the months and years ahead, as we continue our research and application efforts and development of disruptive innovation in the veterinary ophthalmology space," said CEO of Sentrx Animal Care Brian Segebrecht. "Each member brings unique experience in clinical trial design, antiviral modeling, surgical application and overall industry expertise. The board will help ensure we develop and manufacture products that deliver meaningful innovation to the veterinary ophthalmology space."

The members of the Sentrx OSMAB are:

Sarah Atzet, Ph. D.
David Maggs, BVSc (hons), DACVO
Patricia E. Mundy, VetMB MRCVS MA (hons.) DACVO ML (Penn Law)
David Wilkie, DVM, MS, DACVO
D.J Haeussler, DVM, MS, DACVO
Kate Myrna, DVM, MS, DACVO

Full bios: www.sentrxanimalcare.com/OSMAB

Related Information

About Sentrxtm Animal Care, Inc.
Sentrx is a Salt Lake City-based animal health company that was founded on exclusive, worldwide rights to BioHAncetm technology. This patented and proprietary technology uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that produces a cellular scaffolding with unique physical and chemical properties. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals. Sentrx develops and manufactures veterinary ophthalmic and wound care products for companion animals.

To learn more, visit our website at sentrxanimalcare.com.

Mason Williams, Chief Commercial Officer
Sentrxtm Animal Care, Inc.                                                         
(801) 583-2050
[email protected]
570 West 1700 South, Ste 1400
Salt Lake City, UT, 84115

SOURCE Sentrx


These press releases may also interest you

at 06:13
Stride Tech Medical, Inc., https://www.stridetechmedical.com/ (StrideTech) announces the addition of Jack York and Chris Krause to its Advisory Board....

at 06:05
Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101...

at 06:05
NanoString Technologies, Inc. , a leading provider of life science tools for discovery and translational research, today announced a peer-reviewed paper published in Nature Genetics using the GeoMx Human Whole Transcriptome Atlas (WTA) to construct a...

at 06:05
BeiGene , a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab...

at 06:05
Initial results from the TROPION-Lung02 phase 1b trial showed that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in...

at 06:05
St. Catharines-based sterile-fill injectable drug manufacturer Biolyse Pharma Corporation ? has signed a memorandum of understanding with Montreal-based biopharmaceutical PnuVax Incorporated to mass-manufacture a key vaccine in the battle against...



News published on 11 january 2022 at 09:00 and distributed by: